• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Brookline Capital Acquisition Corp.

    2/4/22 8:08:48 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials
    Get the next $BCAC alert in real time by email
    SC 13G 1 p22-0452sc13g.htm BROOKLINE CAPITAL ACQUISITION CORP.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Brookline Capital Acquisition Corp.

    (Name of Issuer)
     

    Class A Common Shares, par value $0.0001 per share

    (Title of Class of Securities)
     

    11374E104

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 11374E10413GPage 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Kepos Capital LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    382,289

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    382,289

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    382,289

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.1%

    12

    TYPE OF REPORTING PERSON

    IA, PN

             

     

    CUSIP No. 11374E10413GPage 3 of 8 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Mark Carhart

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    382,289

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    382,289

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    382,289

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.1%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    CUSIP No. 11374E10413GPage 4 of 8 Pages

     

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Brookline Capital Acquisition Corp. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 280 Park Avenue, Suite 43W, New York, New York 10017.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:
       
      (i) Kepos Capital LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to certain funds and accounts (the "Kepos Funds"), with respect to the Class A Common Shares (as defined in Item 2(d) below) directly held by the Kepos Funds; and
      (ii) Mr. Mark Carhart ("Mr. Carhart"), the managing member of Kepos Capital GP LLC, the general partner of the Investment Manager, with respect to the Class A Common Shares directly held by the Kepos Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Class A Common Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 11 Times Square, 35th Floor, New York, New York 10036.

     

    Item 2(c). CITIZENSHIP:

     

      The Investment Manager is a Delaware limited partnership.  Mr. Carhart is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Class A common shares, par value $0.0001 per share (the "Class A Common Shares").

     

     

    CUSIP No. 11374E10413GPage 5 of 8 Pages

     

     

    Item 2(e). CUSIP NUMBER:
       
      11374E104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ Employee benefit plan or endowment fund in accordance with
    Rule 13d-1(b)(1)(ii)(F);
      (g) x Parent holding company or control person in accordance with
    Rule 13d-1(b)(1)(ii)(G);
      (h) ¨ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: _________________________________

     

    Item 4. OWNERSHIP.

     

       

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    The percentages set forth herein are calculated based upon 7,434,500 Class A Common Shares outstanding as of December 8, 2021 as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the Securities and Exchange Commission on December 9, 2021.

     

     

    CUSIP No. 11374E10413GPage 6 of 8 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The Kepos Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Class A Common Shares reported herein.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 11374E10413GPage 7 of 8 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 4, 2022

     

     

    KEPOS CAPITAL LP
         
         
    By: /s/ Simon Raykher  
    Name: Simon Raykher  
    Title: General Counsel  
         
         
    /s/ Mark Carhart  
    MARK CARHART  
         

     

     

     

     

     

    CUSIP No. 11374E10413GPage 8 of 8 Pages

     

    EXHIBIT 1

    JOINT ACQUISITION STATEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATED: February 4, 2022

     

     

    KEPOS CAPITAL LP
         
         
    By: /s/ Simon Raykher  
    Name: Simon Raykher  
    Title: General Counsel  
         
         
    /s/ Mark Carhart  
    MARK CARHART  
         

     

     

     

     

    Get the next $BCAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCAC
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Brookline Capital Acquisition Corp.

    S-1/A - Brookline Capital Acquisition Corp II (0002102072) (Filer)

    2/10/26 5:07:10 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 10-Q filed by Brookline Capital Acquisition Corp.

    10-Q - Apexigen, Inc. (0001814140) (Filer)

    11/14/22 5:13:36 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Brookline Capital Acquisition Corp. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Other Events, Financial Statements and Exhibits

    8-K - Apexigen, Inc. (0001814140) (Filer)

    11/14/22 4:07:21 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apexigen to Participate in the Brookline Capital Markets Newport Symposium

    SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen's Management will participate in the Brookline Capital Markets Newport Symposium, to be held in Newport, Rhode Island on Monday, July 18, 2022. Brookline Capital Markets Newport SymposiumFormat: Apexigen presentation and 1-on-1 meetingsDate: Monday, July 18, 2022Location: Newport, Rhode Island Please contact your Brookline Capital Markets sales representative for additional information. About Apexigen, Inc.Apexigen is a clinical-st

    7/11/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Announces Board Appointment and New Chair

    SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

    6/29/22 4:05:00 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Appoints William Duke as Chief Financial Officer

    SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

    6/8/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Wong Amy covered exercise/tax liability with 2,851 shares, decreasing direct ownership by 17% to 13,637 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:57:25 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Sarena Francis Willard covered exercise/tax liability with 6,916 shares, decreasing direct ownership by 17% to 33,084 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:49:39 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4: Hsu Frank J. covered exercise/tax liability with 4,323 shares, decreasing direct ownership by 17% to 20,677 units

    4 - Apexigen, Inc. (0001814140) (Issuer)

    12/19/22 5:41:54 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Leadership Updates

    Live Leadership Updates

    View All

    Apexigen Announces Board Appointment and New Chair

    SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp

    6/29/22 4:05:00 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    Apexigen Appoints William Duke as Chief Financial Officer

    SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon

    6/8/22 8:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Brookline Capital Acquisition Corp.

    SC 13G - Apexigen, Inc. (0001814140) (Subject)

    8/8/22 12:18:48 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Brookline Capital Acquisition Corp. (Amendment)

    SC 13G/A - Brookline Capital Acquisition Corp. (0001814140) (Subject)

    8/1/22 3:48:29 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G filed by Brookline Capital Acquisition Corp.

    SC 13G - Brookline Capital Acquisition Corp. (0001814140) (Subject)

    4/13/22 3:32:08 PM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials

    $BCAC
    Financials

    Live finance-specific insights

    View All

    Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company

    - Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen's lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol "APGN" - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022

    3/18/22 6:00:00 AM ET
    $BCAC
    Consumer Electronics/Appliances
    Industrials